本次范围审查旨在确定与成釉细胞瘤复发相关的因素。根据董事会研究问题“哪些因素与成釉细胞瘤复发相关？”，在 PubMed、Scopus 和 EMBASE 中进行了系统检索。纳入了针对与复发性成釉细胞瘤相关的风险和预防因素的英语观察性研究，并提取了数据。83 项回顾性观察性研究符合纳入标准。已确定的复发预后因素包括：(1) 肿瘤大小/直径/体积，(2) 皮质骨穿孔/软组织侵犯，(3) 多房性射线可透性，(4) 受影响的牙齿涉及病变，(5) 牙根吸收， (6) WHO 分类 - 传统（实性/多囊性）成釉细胞瘤，(7) 组织学亚型 - 单囊性成釉细胞瘤壁侵犯，(8) 保守治疗方式 - 简单剜除术、刮除术和有袋造血术，以及 (9) 非摘除/保留涉及的牙齿。没有强有力的证据将免疫组织化学表达与复发联系起来。有趣的是，尽管 BRAF p.V600E 在成釉细胞瘤中很常见，但在复发方面仍然存在争议。成釉细胞瘤的某些临床特征、影像学表现、组织学亚型和治疗选择可以帮助识别具有高复发风险的患者。需要进一步的前瞻性研究来评估预后因素模型和免疫组织化学研究。© 2024。作者获得 Springer Science Business Media, LLC（Springer Nature 旗下公司）的独家许可。

This scoping review aimed to identify factors associated with the recurrence of ameloblastoma.Systematic searches were conducted in PubMed, Scopus, and EMBASE, based on the board research question: "What factors are related to the recurrence of ameloblastoma?". English-language observational studies addressing the risk and preventive factors associated with recurrent ameloblastoma were included and data were extracted.Eighty-three retrospective observational studies met the inclusion criteria. The identified prognostic factors for recurrence included: (1) Tumor size/diameter/volume, (2) cortical bone perforation/ soft tissue invasion, (3) multilocular radiolucency, (4) impacted tooth-involving lesions, (5) root resorption, (6) WHO classification - conventional (solid/multicystic) ameloblastoma, (7) histological subtype - mural invasion of unicystic ameloblastoma, (8) conservative treatment modalities - simple enucleation, curettage, and marsupialization, and (9) non-extraction/preservation of involved teeth. No strong evidence linked immunohistochemical expression to recurrence. Interestingly, BRAF p.V600E remained controversial in terms of recurrence, despite being a frequent finding in ameloblastoma.Certain clinical characteristics, radiographic findings, histological subtypes, and treatment choices of ameloblastoma can help identify patients at high risk of recurrence. Further prospective studies to evaluate the prognostic factor model and research on immunohistochemistry are required.© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.